Gilead Sciences
(NQ:
GILD
)
76.77
+0.28 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
July 08, 2024
Via
Benzinga
Amgen, Inc. Dividend Stock Analysis
July 05, 2024
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis.
Via
Talk Markets
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
Key Takeaways From Gilead Sciences Analyst Ratings
July 01, 2024
Via
Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
June 24, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
June 19, 2024
Via
Benzinga
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
3 Magnificent Stocks Retirees Can Buy and Hold Forever
July 01, 2024
These stocks could be ideal for investors in their golden years.
Via
The Motley Fool
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
June 28, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 25, 2024
Via
Benzinga
7 Dividend Stocks to Buy Now: June 2024
June 23, 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands.
Via
InvestorPlace
What 8 Analyst Ratings Have To Say About Gilead Sciences
June 14, 2024
Via
Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
June 23, 2024
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%).
Via
Benzinga
Top Analyst Reports For Abbott, BP & Gilead
June 21, 2024
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and...
Via
Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
June 21, 2024
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
June 21, 2024
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir.
Via
Benzinga
Pre-Market Movers - June 21, 2024
June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers.
Via
Talk Markets
Defying the Norms: 3 High P/E Stocks With Room to Run
June 21, 2024
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations.
Via
InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
June 20, 2024
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
June 20, 2024
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa.
Via
Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
June 20, 2024
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,...
Via
Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
June 20, 2024
Via
Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
June 17, 2024
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.
Via
Benzinga
Topics
Death
Exposures
Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
June 13, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.